Oppenheimer analyst Leland Gershell maintains NuCana (NASDAQ:NCNA) with a Outperform, adjusts target to $150 from $4 (1-25 Reverse Stock Split)
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/30/2024 | Outperform → Mkt Perform | William Blair | |
| 3/3/2022 | Outperform → Market Perform | Cowen & Co. | |
| 11/24/2021 | $10.00 → $9.00 | Buy | HC Wainwright & Co. |
EDINBURGH, United Kingdom, Sept. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced that it has received formal notification from The Nasdaq Stock Market on September 4, 2025 confirming that the Company is in compliance with all applicable Nasdaq continued listing criteria, including the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). As such, the previously disclosed Nasdaq listing matter has been closed. "As a result of the decisive steps we have taken, NuCana is now fully compliant with Nasdaq's continued listing standards," said Andrew Kay, NuCana's Executive Chairman. "We anticipate our existing cash resources, which
EDINBURGH, United Kingdom, Sept. 03, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced a presentation at the upcoming annual European Society for Medical Oncology ("ESMO") congress being held October 17-21, 2025 in Berlin, Germany (the "ESMO Congress 2025"). The details of NuCana's presentation at the meeting are as follows: Abstract Title: Patient Derived Organoids Reveal Synergy Between NUC-7738 and PD-1 Inhibition in Renal Cell Cancer Poster Number: 1530PSession: Investigational ImmunotherapyDate: Sunday, October 19, 2025Presenting Author: H. Abdullah All regular abstracts accepted for presentation at the ESMO Congress 2025 will be published onli
First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Remain on track for 2025 Strategic Execution of ATM Offering Extends Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Aug. 20, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced financial results for the second quarter ended June 30, 2025 and provided an update on its clinical development pr
6-K - NuCana plc (0001709626) (Filer)
6-K - NuCana plc (0001709626) (Filer)
6-K - NuCana plc (0001709626) (Filer)
William Blair downgraded NuCana from Outperform to Mkt Perform
Cowen & Co. downgraded NuCana from Outperform to Market Perform
HC Wainwright & Co. reiterated coverage of NuCana with a rating of Buy and set a new price target of $9.00 from $10.00 previously
EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb, and has a strong track record of leading clinical strategy and development efforts for numerous programs at all stages of development. "We are thrilled to welcome Dr. Levy to our Board of Directors," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "He is a recognized
EDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer. Dr. Bloss will be based in NuCana's US offices located outside Boston, MA. "We are delighted to welcome Jeff to the executive team at NuCana," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Jeff brings over two decades of experience leading clinical development and medical affairs at several biotechnology and pharmaceutical companies. His achievements include leading the development, approval and
SC 13G/A - NuCana plc (0001709626) (Subject)
SC 13D/A - NuCana plc (0001709626) (Subject)
SC 13G/A - NuCana plc (0001709626) (Subject)